APOL1 and COVID-19: ACE polymorphisms and the high-risk apolipoprotein L1 (APOL1) genotype variants have been recently described as genetic modifiers associated with a higher proinflammatory state and podocyte damage in patients with coronavirus diseases (COVID-19) [6].